𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

✍ Scribed by Kantarjian, Hagop; Shah, Neil P.; Hochhaus, Andreas; Cortes, Jorge; Shah, Sandip; Ayala, Manuel; Moiraghi, Beatriz; Shen, Zhixiang; Mayer, Jiri; Pasquini, Ricardo

Book ID
111694594
Publisher
Massachusetts Medical Society
Year
2010
Tongue
English
Weight
260 KB
Volume
362
Category
Article
ISSN
0096-6762

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

High-dose imatinib for newly diagnosed c
High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patientsβ€”Systematic review and meta-analysis
✍ Anat Gafter-Gvili; Avi Leader; Ronit Gurion; Liat Vidal; Ron Ram; Adi Shacham-Ab πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 319 KB πŸ‘ 1 views

## Abstract Imatinib at a dose of 400 mg daily is considered frontline treatment in chronic phase chronic myeloid leukemia (CP‐CML). We conducted a systematic review and meta‐analysis of randomized controlled trials comparing frontline treatment with imatinib 400 mg daily versus higher doses (β‰₯600

Cost-effectiveness of imatinib versus in
Cost-effectiveness of imatinib versus interferon-Ξ± plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia
✍ Shelby D. Reed; Kevin J. Anstrom; Jennifer A. Ludmer; G. Alastair Glendenning; K πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 119 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Despite a lack of long‐term data, imatinib has become standard therapy for patients with newly diagnosed chronic‐phase chronic myeloid leukemia (CML) who are not candidates for allogeneic stem cell transplantation. In the current study, the authors estimated the increment